Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00532155 · ClinicalTrials.gov registry record · Phase 3
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 913
- Enrollment target
NCT00532155 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 913 participants.
The verdict
NCT00532155, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 913 participants
- Enrollment target
Study Summary
The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC). The secondary objectives were to compare other efficacy parameters, to assess the overall safety of the two treatment arms, to assess the pharmacokinetics of intravenous (IV) aflibercept in this participant population and to determine immunogenicity of IV aflibercept in all participants.
Interventions
- DRUG Placebo
- DRUG Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- DRUG Docetaxel (Taxotere®)
- DRUG Dexamethasone (pre- and post-medication for docetaxel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 913 participants |
| Start Date | 2007-09 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00532155
The ClinicalTrials.gov registry entry for NCT00532155 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 913 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00532155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00532155 about?
NCT00532155 is a clinical study titled "A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer". The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC). The secondary objectives were to compare o...
What is the current status of trial NCT00532155?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 913 participants. The study started on 2007-09. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00532155?
The interventions under investigation include: Placebo (DRUG), Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) (DRUG), Docetaxel (Taxotere®) (DRUG), Dexamethasone (pre- and post-medication for docetaxel) (DRUG).
Who is sponsoring clinical trial NCT00532155?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.